Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's ...

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025 ...

There are two kinds of risk factors for dementia: non-modifiable and modifiable. Non-modifiable risk factors are ones that cannot be changed or eliminated, like aging, family history and genetics.

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Borrowers with a severe permanent disability who are unable to repay their Canada Student Loans may be eligible to have their debt cancelled through the Severe Permanent Disability Benefit. You have ...

BERLIN--(BUSINESS WIRE)--Bayer today announced positive topline results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor ...

The Montreal Cognitive Assessment (MoCA) is a test used to detect mild cognitive decline and early signs of dementia ... The test is harder than the MMSE and less informative in people with moderate ...

Progress in dementia research and clinical care has continued to accelerate in 2024. Monoclonal antibody anti-amyloid immunotherapies (AATs) have been approved for clinical use for patients with mild ...

(“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s ty ...

As a result, a person with dementia may find it quite exhausting to do relatively simple tasks like communicating, eating or trying to understand what is going on around them. This can make the person ...